Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomized trials.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials – The Lancet Oncology

Commentary on Twitter

@OncoAlert Success of a monoclonal antibody when @ right target – 10 yr benefits of trastuzumab – #EBCTCG meta-analysis (N>13,000):
?Impressive absolute and relative ~1/3 reduced deaths, ~1/3 recurrences
?ER-: Recur⬇️ 11%
?ER+: Recur⬇️ 8%@kevinpunie @prat_aleix @itsnot_pink https://t.co/O1WKcEEuGG

— Nicole Kuderer (@NicoleKuderer) August 4, 2021